Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved doxorubicin in combination with cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th) for reimbursement as a treatment option for the neoadjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.
This statement is based on a regulatory approval from the Health Service Executive:
Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.